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ABSTRACT
Objective To examine the association of lipid-lowering
drugs, change in diet and physical activity with
a decline in low-density lipoprotein (LDL) cholesterol in
middle age.
Design A prospective cohort study.
Setting The Whitehall II study.
Participants 4469 British civil servants (72% men) aged
39e62 years at baseline.
Main Outcome Measure Change in LDL-cholesterol
concentrations between the baseline (1991e3) and
follow-up (2003e4).
Results Mean LDL-cholesterol decreased from 4.38 to
3.52 mmol/l over a mean follow-up of 11.3 years. In
a mutually adjusted model, a decline in LDL-cholesterol
was greater among those who were taking lipid-lowering
treatment at baseline ( 1.14 mmol/l, n¼34), or started
treatment during the follow-up ( 1.77 mmol/l, n¼481)
compared with untreated individuals (n¼3954;
p<0.001); among those who improved their
dietdespecially the ratio of white to red meat
consumption and the ratio of polyunsaturated to
saturated fatty acids intaked( 0.07 mmol/l, n¼717)
compared with those with no change in diet (n¼3071;
p¼0.03) and among those who increased physical
activity ( 0.10 mmol/l, n¼601) compared with those
with no change in physical activity (n¼3312; p¼0.005).
Based on these estimates, successful implementation of
lipid-lowering drug treatment for high-risk participants
(n¼858) and favourable changes in diet (n¼3457) and
physical activity (n¼2190) among those with non-
optimal lifestyles would reduce LDL-cholesterol by 0.90
to 1.07 mmol/l in the total cohort.
Conclusions Both lipid-lowering pharmacotherapy and
favourable changes in lifestyle independently reduced
LDL-cholesterol levels in a cohort of middle-aged men
and women, supporting the use of multifaceted
intervention strategies for prevention.
Blood cholesterol, low density lipoprotein (LDL)
cholesterol in particular, is a major risk factor for
coronary heart disease (CHD).
1 Large randomised
controlled trials and meta-analyses
2e4 have estab-
lished the clinical beneﬁts of lowering LDL-choles-
terol. A decrease of 1 mmol/l in LDL-cholesterol
concentrations has been shown to be associated
with a 23% lower risk of myocardial infarction or
coronary death.
4 Similarly, a 10% reduction in total
cholesterol was associated with a 20% reduction in
the risk of CHD.
5
There is now consistent evidence for a secular
decline in total cholesterol and LDL-cholesterol
levels among adults in industrialised countries.
6e19
For example, the MONICA study showed total
cholesterol in adults aged 35e64 years to have
declined between the mid-1980s and mid-1990s in
approximately half of the European populations
included in the study.
6 Similar ﬁndings have been
reported in other European populations,
8e12 the
USA,
13e16 Canada,
17 Australia
18 and New
Zealand.
19
Clinical guidelines recommend a multifaceted
approach to lowering LDL-cholesterol.
1 20 However,
the extent to which a healthy diet, physical activity
and lipid-lowering drugs independently explain the
decline in LDL-cholesterol levels currently being
observed at the population level is unknown. We
therefore examined associations of lipid-lowering
drug use and 11-year change in diet and physical
activity with declining LDL-cholesterol trends in an
occupational cohort of middle-aged British civil
servants participating in the Whitehall II study.
SUBJECTS AND METHODS
Study sample
The Whitehall II study is a prospective cohort
study of 10308 (67% men) London-based British
civil servants aged 35e55 years in 1985.
21 The
baseline examination (phase 1) took place during
1985e8 and involved a clinical examination and
self-administered questionnaire. Subsequent phases
of data collection have alternated between postal
questionnaire alone (phases 2 (1988e90),
4 (1995e6), 6 (2001) and 8 (2006)), and postal
questionnaire accompanied by a medical screening
(phases 3 (1991e3), 5 (1997e9) and 7 (2002e4)).
Detailed lipid data were not available at phase 1
so the data used in the current analysis were drawn
from phases 3e7, making phase 3 the baseline for
the present study. The mean follow-up between
phases 3 and 7 was 11.3 years (SD¼0.5). Partici-
pants not included in the analysis were those who
did not undertake the medical screening at phases 3
or 7, and those with missing data on any of the
predictors (lipid-lowering drugs, diet and physical
activity) or potential confounders (ethnicity, body
mass index, level of education, smoking status and
the presence of long-standing illness) either at
phase 3 or phase 7 (ﬁgure 1). A total of 4469
participants was eligible and constituted the study
sample. Ethical approval for the Whitehall II study
< Additional appendix tables
are published online only. To
view these ﬁles please visit the
journal online (http://heart.bmj.
com).
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Epidemiologywas obtained from the University College London Medical
School committee on the ethics of human research (London,
UK).
Biochemical analyses
Blood samples were collected at phases 3 and 7, following either
an 8-h overnight fast (participants presenting to the clinic in the
morning) or at least a 4-h fast after a light fat-free breakfast
(participants presenting in the afternoon). Venepuncture of the
left antecubital vein was performed with tourniquet. Blood was
collected into plain and ﬂuoride Sarstedt (Neumbrecht,
Germany) monovettes. Serum for lipid analyses was refrigerated
at  48C and assayed within 72 h.
22 Total cholesterol was
determined by an enzymatic procedure using the CHODePAP
method at phases 3 and 7. Serum high-density lipoprotein
(HDL) cholesterol concentrations were measured from the
supernatant after the precipitation of non-HDL-cholesterol with
dextran sulphateemagnesium at phase 3 and with a direct
homogeneous assay at phase 7,
23 using at both phases the
CHODePAP method. Serum triglyceride was determined by
the enzymatic colorimetric method (GPOePAP) at both phases.
The concentration of LDL-cholesterol was calculated using the
Friedewald formula when serum triglycerides were lower than
4.5 mmol/l.
24 Technical error was estimated by assaying blinded
duplicate samples for 5% of subjects. Coefﬁcients of variation
were 2.0e6.6%. After both screenings, participants were sent
a letter that informed them of their results and summarised
whether or not they were ‘at increased risk of heart disease or
angina’. For example, when a total cholesterol level of 8.5 mmol/
l or higher was recorded at baseline (n¼185), the letter suggested
the participant see his or her general practitioner for a repeat
test. The same envelope contained a similar unsealed letter
addressed to the participant’s general practitioner.
Potential predictors
Lipid-lowering drugs
At phases 3 and 7, participants were asked whether they had
taken any medication in the past 14 days and, if so, to provide
the name of the medication. Medications were coded using
British National Formulary codes. We did not distinguish statins
from other lipid-lowering drugs, such as ﬁbrates, nicotinic acid
and its derivatives, cholesterol absorption inhibitors, or omega-3
fatty acid compounds. Our measure thus included all lipid-
lowering drugs combined together.
Diet quality using the AHEI
Diet quality was measured using the alternate healthy eating
index (AHEI).
25 Based on the 127-item anglicised version of
Willett’s food frequency questionnaire (FFQ),
26 27 it has been
found to yield a satisfactory estimate of food intake among
Whitehall II participants compared with biomarkers and 7-day
diet diaries.
27 The AHEI includes nine food components; food
items listed on the FFQ were assigned to their appropriate food
groups, using the FFQ serving sizes identiﬁed. Eight of the nine
components (vegetables, fruit, nuts and soy protein, ratio of
white to red meat, dietary ﬁbre, trans fat, ratio of poly-
unsaturated to saturated fatty acids and alcohol) contributed
0e10 points to the total AHEI score. A score of 10 indicates that
recommendations were fully met, whereas a score of 0 repre-
sents the least healthy dietary behaviour. Intermediate intakes
were scored proportionally between 0 and 10. The ﬁnal
component, long-term multivitamin use, was dichotomised,
contributing either 2.5 points (for non-use) or 7.5 points (for
use) to the total score. All component scores were summed to
obtain a total AHEI score ranging from 2.5 (worst) to 87.5
(best).
25 Nutrient intake estimates were calculated using
a computerised system developed for the Whitehall II dietary
data.
27
Physical activity
At baseline (phase 3), participants were asked the duration
(number of hours per week) of their participation in moderately
energetic (eg, dancing, cycling, leisurely swimming, lawn
mowing) and vigorous (eg, running, hard swimming, playing
squash) physical activity. At phase 7, the questionnaire was
modiﬁed to include 20 items on the duration of participation in
different physical activities (eg, running, cycling, other sports,
housework and gardening activities) that were used to compute
hours per week at each intensity level. At both phases, physical
activity was deﬁned as the total number of hours per week spent
in moderate and vigorous activity.
Covariates
Other variables included in the analysis were: sex; age at baseline
(<45, 45e54, $55 years); self-reported ethnicity (white, non-
white); education (none, lower secondary, A-levels, university or
higher); current smoking (categorised as yes or no); and long-
standing illness (categorised as yes or no). Prevalent CHD was
deﬁned using the MONICA criteria,
28 positive responses to
questions about chest pain
29 and physician diagnoses, evidence
from medical records, or ECG ﬁndings. Prevalent diabetes
Phase 1 (1985-1988) respondents (n=10 308)
Excluded (n=1493):
Died (n=107)
Lost to follow-up (n=1)
Non respondents at phase 3 (n=1385)
Phase 3 (1991-1993) respondents (n=8815)
Excluded (n=1232):
Missed screening or questionnaire (n=885)
Missing LDL-C despite attending screening (n=211)
Missing diet data (n=63)
Missing physical activity data (n=55)
Missing BMI (n=23)
Missing data on smoking status (n=3)
Included at phase 3 (n=7583)
Excluded (n=1508):
Died (n=268)
Lost to follow-up (n=3)
Non respondents at phase 7 (n=1237)
Phase 7 (2003-2004) respondents (n=6075)
Excluded (n=1606):
Missed screening or questionnaire (n=375)
Missing LDL-C despite attending screening (n=115)
Missing lipid lowering drug data (n=2)
Missing diet data (n=727) g
Missing physical activity data (n=67)
Missing BMI (n=22)
Missing ApoE genotype (n=249)
Missing data on education (n=220)
Missing data on smoking status (n=7)
Missing data on presence of longstanding illness (n=4)
Included at phase 7 (n=4469)
Figure 1 Selection of the study participants. ApoE, apolipoprotein E;
BMI, body mass index; LDL-C, low-density lipoprotein cholesterol.
924 Heart 2011;97:923e930. doi:10.1136/hrt.2010.216309
Epidemiologymellitus was deﬁned as reported doctor-diagnosed diabetes
mellitus or the use of diabetes medication.
30 Body mass index
(BMI) was calculated as weight in kilograms divided by height in
metres squared and categorised as normal (BMI <25), over-
weight (25 #BMI <30), or obese (BMI $30).
31
Statistical analyses
The 11-year change in LDL-cholesterol was calculated as phase 7
minus phase 3 values. In the analysis we wanted to determine
the impact of the predictors assessed at baseline (phase 3) and
their values over the 11-year follow-up. In order to simplify the
interpretation of the coefﬁcients, we categorised the predictors
in the following way: lipid-lowering drug use was categorised as
no use, treated at baseline, or treatment started during the
follow-up. Change in diet was estimated by subtracting the
AHEI score at baseline from that at phase 7, standardised to
a z-score (mean 0, SD 1) and categorised as ‘increase’ (z-score
$1), ‘stable’ ( 1# z-score <1) and ‘decrease’ (z-score # 1).
This procedure was ﬁrst applied to the total AHEI score and
then to the nine components of the score. Change in physical
activity was calculated by subtracting the number of hours per
week of physical activity at baseline from that at phase 7. The
difference in duration was standardised and categorised as
an ‘increase’ (z-score $1), ‘stable’ ( 1# z-score <1), ‘decrease’
(z-score # 1) level of physical activity.
As 11-year changes in LDL-cholesterol, diet score and physical
activity were all normally distributed, parametric statistical tests
were used in the analysis. To examine the unadjusted impact of
the predictors (lipid-lowering drug, diet and physical activity)
and the covariates we ﬁrst conducted univariate analysis using
linear regression with change in LDL-cholesterol as the depen-
dent variable. The interaction terms between the predictors and
sex and age had p values greater than 0.05, negating any neces-
sity to stratify the analyses by age or sex. For the quantitative
predictors (diet and physical activity) and for change in BMI, we
tested the interaction between continuous values at baseline and
the change measures expressed as ‘increase’, ‘stable’,o r‘decrease’.
Only the interaction term between BMI at baseline and change
in BMI was signiﬁcant (p<0.05) and was consequently included
in further analyses as a covariate.
We constructed three models to examine associations between
the predictors and concomitant change in LDL-cholesterol.
Model 1 included only non-modiﬁable covariates (sex, age at
baseline, ethnicity) and the duration of follow-up. Model 2
further included education, BMI and long-standing illness at
baseline. Model 3 included all three predictors together with the
covariates already in model 2. To examine the role of regression
to the mean in declining LDL-cholesterol trends, we repeated
model 3 among participants in the highest quintile of LDL-
cholesterol at baseline (in this subgroup regression to the mean
is particularly likely),
32 and compared the results with those
from the main analysis. In addition, for lipid-lowering medica-
tion we removed any potential regression to the mean effect by
comparing those with lipid-lowering medication during follow-
up with a group without medication selected such that their
mean LDL-cholesterol values at baseline were identical.
Using the covariates and predictors in model 3, we conducted
several supplementary analyses to determine: (1) whether
speciﬁc components of the nine-item AHEI scale were associated
with the reduction in LDL-cholesterol; (2) the effect of moderate
and vigorous physical activity separately on change in LDL-
cholesterol; (3) the impact of further adjusting model 3 for
change in BMI and the interaction term between change in BMI
and BMI at baseline; and (4) whether replacing the variable
‘presence of a long-standing illness at baseline’ by the variables
‘presence of at least one non-fatal CHD event at baseline’
and ‘presence of diabetes mellitus at baseline’ changed estimates.
The squared multiple correlation, also called coefﬁcient of
determination (R
2), was used to estimate the proportion of
variation in LDL-cholesterol change explained by the predictors.
We assessed change in R
2 when each predictor was entered
individually into the initial model adjusted for sex, age at
baseline, ethnicity, duration of follow-up, education level, BMI
at baseline and long-standing illness at baseline; the model above
plus mutual adjustment for the predictors.
33
To examine potential beneﬁcial effects related to lipid-
lowering drug treatment and favourable changes in diet and
physical activity, we estimated the reduction in LDL-cholesterol
that would be observed if all participants in need of lipid-
lowering drugs at baseline (n¼858) were treated, all individuals
with a non-optimal diet (AHEI score <60, n¼3457) improved
their diet, deﬁned as an increased AHEI score of at least 1 SD (0.6
point), and those who undertake less than the recommended
level of physical activity (<2.5 h/week, n¼2190) increased their
physical activity, deﬁned as a minimum increase of 17 min
(1 SD) physical activity per week. Following European guide-
lines,
20 participants with prevalent CHD or diabetes and those
with a ‘high risk’ of cardiovascular disease (CVD) deﬁned as
having a 10-year risk of CVD death of 5% or more based on the
systematic coronary risk evaluation (SCORE) charts,
34 were
deemed to be in need of lipid-lowering therapy. The beneﬁts of
lipid-lowering treatment, improved diet ($1 SD) and increased
physical activity levels ($1 SD) for the total population were
estimated based on model 3 estimates using the following
equation:
b y¼ intercept + b1I treatment at baseline + b2I treatment during the follow-up
+ b3I one or more SD decrease in AHEI score + b4I one or more SD increase in
AHEI score + b5I one or more SD decrease in hours of physical activity + b6I one
or more SD increase in hours of physical activity + b7 men + b8 age at
baseline + b9 ethnicity + b7I intermediate education + b8I high education
+ b9 BMI at baseline + b10 long-standing illness + b11 duration of
follow-up,
where b y is a change in LDL cholesterol and I an indicator
variable (1 vs 0). All analyses were performed using SAS
software, version 9.
RESULTS
Description of the study participants
Of the 10308 participants at recruitment to the study, 7583 had
complete data at phase 3 and 4469 were included in the analysis
reported here (ﬁgure 1, comparison of the participants included
in the analyses with those excluded is provided in supplemen-
tary appendix, eTable 1, available online only). Table 1 describes
the characteristics of those included at baseline and follow-up.
The mean age at baseline was 49.3 years and 72.0% were men.
From baseline to follow-up, the mean LDL-cholesterol concen-
tration dropped from 4.38 to 3.52 mmol/l. At the same time the
use of lipid-lowering drugs increased from 0.8% to 10.8%. There
was a small increase in the mean total AHEI score (from 50.7 to
51.2) and the mean number of hours per week spent in moderate
or vigorous physical activity (from 3.4 to 3.7 h/week).
At baseline, 858 participants had a high risk of CVD according
to the European guidelines,
20 had diabetes or had experienced
a validated non-fatal CHD event at baseline, or took lipid-
lowering medication at baseline or follow-up. Only 60.0%
(n¼515) of them were taking lipid-lowering medication at
follow-up.
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EpidemiologyMultivariate analysis of change in lipid levels during follow-up
Univariate analyses provided strong evidence of associations
between changes in LDL-cholesterol and all the covariates, with
the exception of smoking (see supplementary appendix eTable 2,
available online only). Table 2 presents multivariable-adjusted
absolute changes in LDL-cholesterol as a function of lipid-
lowering medication and changes in diet and physical activity.
These results show that LDL-cholesterol declined in all groups.
Table 3 shows the corresponding changes in relative terms.
Compared with those not on lipid-lowering drugs, the decline in
LDL-cholesterol was greater among those who were on treat-
ment at baseline or during the follow-up. Compared with those
with a stable diet, individuals who improved their diet showed
a greater decline in LDL-cholesterol, whereas those whose diet
worsened showed a smaller decline. Similar results were
observed for physical activity. All relative differences persisted
after serial adjustments for multiple covariates (table 3). The
results were largely similar in a subgroup of participants in the
top quintile of LDL-cholesterol at baseline and when, for lipid-
lowering medication, potential regression to the mean effects
were totally removed (see supplementary appendix eTable 3,
available online only).
More detailed analyses of the nine components of the AHEI
diet score and intensity of physical activity are shown in
supplementary appendix eTables 4 and 5 (available online only).
Brieﬂy, the decline in LDL-cholesterol change was signiﬁcantly
associated with an increase in the ratio of white to red meat
consumption (p<0.001), the ratio of polyunsaturated to satu-
rated fatty acids (p<0.001), an increase in fruit consumption
(p¼0.04) and a decrease in trans fats (p¼0.04). Decreases in both
moderate and vigorous physical activity were associated with
a smaller decrease in LDL-cholesterol.
In sensitivity analyses, we examined the role of BMI by
adding the following covariates to model 3: change in BMI and
the interaction term between change in BMI and BMI at base-
line. The results remained largely unchanged. Similarly, when
the variable ‘presence of a long-standing illness at baseline’ was
replaced by the variables ‘presence of at least one non-fatal CHD
event at baseline’ and ‘presence of diabetes mellitus at baseline’,
respectively, in model 3, the results were much the same (data
not shown).
Multivariate analyses of changes in other lipid fractions are
provided in supplementary appendix, eTable 6 (available online
only). An increase in physical activity was associated with
a 0.05 mmol/l greater increase in HDL-cholesterol compared
with those who had a stable level of physical activity. Partici-
pants whose BMI increased over the follow-up showed
a 0.01 mmol/l decrease in HDL-cholesterol and a 0.27 mmol/l
Table 1 Baseline (phase 3) and follow-up (phase 7) characteristics of the 4469 study participants
Baseline (1991e3) Phase 7 (2003e4)
N %/Mean (SD) N %/Mean (SD)
Sex
Men 3217 72.0 ee
Women 1252 28.0 ee
Age (years)
<45 1198 26.8 ee
45e55 2169 48.5 ee
$55 1102 24.7 ee
All 4469 49.3 (5.9) ee
Ethnicity
White 4189 93.7 ee
Non-white 280 6.3 ee
Education
No or lower secondary 1969 44.1 ee
A-levels 1171 26.2 ee
University or higher 1329 29.7 ee
BMI (kg/m
2)
Normal (<25) 2463 55.1 1718 38.4
Overweight (25e30) 1667 37.3 1999 44.7
Obese ($30) 339 7.6 752 16.8
All 4469 25.0 (3.5) 4469 26.5 (4.2)
Current smoking
No 4000 89.5 4159 93.1
Yes 469 10.5 310 6.9
Long-standing illness
No 2993 67.0 1767 39.5
Yes 1476 33.0 2702 60.5
Total cholesterol concentrations (mmol/l) 4469 6.4 (1.1) 4469 5.7 (1.0)
HDL-cholesterol concentrations (mmol/l) 4469 1.4 (0.4) 4469 1.6 (0.4)
Triglyceride concentrations (mmol/l) 4469 1.3 (0.7) 4469 1.3 (0.7)
LDL-cholesterol concentrations (mmol/l) 4469 4.4 (1.0) 4469 3.5 (0.9)
Lipid-lowering drugs use
No 4435 99.2 3987 89.2
Yes 34 0.8 482 10.8
AHEI score, mean (SD) 4469 50.7 (11.9) 4469 51.2 (12.5)
Physical activity (h/week) 4469 3.4 (3.4) 4469 3.7 (3.1)
AHEI, alternate healthy eating index; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Epidemiologyincrease in triglycerides; among those with stable BMI, HDL-
cholesterol increased by 0.11 mmol/l and triglycerides decreased
by 0.07 mmol/l. Participants whose alcohol consumption
increased had a 0.08 mmol/l greater increase in HDL-cholesterol
than those whose alcohol consumption was stable. Among
participants who stopped smoking during follow-up, there was
a 0.04 mmol/l greater increase in HDL-cholesterol compared
with never smokers.
Relative importance of medications, diet and physical activity
in explaining LDL-cholesterol trends
The baseline model for this analysis, including sex, ethnicity,
duration of follow-up and baseline measures of age, education,
BMI and long-standing illness as covariates, explained 11.6% of
the variability in the change in LDL-cholesterol. Adding lipid-
lowering drugs to this model increased the coefﬁcient of deter-
mination (R
2) by 29.4%. AHEI diet score and physical activity,
when added into the baseline model, explained only 0.5% and
0.3% of the variability in the change in LDL-cholesterol
concentrations, respectively. Each predictor had an independent
effect in the mutually adjusted model. (see supplementary
appendix eTable 7, available online only).
Estimated population-level beneﬁts of lipid-lowering drugs and
improved lifestyle
Based on model 3 estimates, if all 858 participants with preva-
lent CHD or diabetes or a high risk of CVD death at baseline had
been on lipid-lowering medication, as suggested in the European
guidelines, then the decline in LDL-cholesterol would have been
2.77 mmol/l greater than the observed value (table 4). If all 3457
participants who did not have an optimal diet (AHEI score <60)
had improved their diet, the corresponding additional decline in
LDL-cholesterol would have been 0.08 mmol/l. The adoption of
a more physically active lifestyle by the 2190 participants who
undertook less than 2.5 h of moderate or vigorous activities per
week would have produced an additional decline in LDL-
cholesterol of 0.11 mmol/l. These estimations applied to the
total cohort (n¼4469) suggest that successful implementation of
lipid-lowering therapy and change in lifestyle would each reduce
LDL-cholesterol levels by 0.90 to 1.07 mmol/l (table 4).
Table 2 Absolute change in serum LDL-cholesterol between the baseline (1991e3) and follow-up
(2003e4) screening as a function of the use of lipid-lowering drugs, healthy diet and physical activity
(N¼4469)
n
Mean absolute change in LDL-cholesterol (95% CI), mmol/l
Model 1* Model 2y Model 3z
Start of lipid-lowering drugs
None 3954  0.61 ( 0.66 to  0.56)  0.60 ( 0.65 to  0.56)  0.59 ( 0.65 to  0.53)
Baseline 34  1.70 ( 1.96 to  1.43)  1.70 ( 1.96 to  1.43)  1.73 ( 1.99 to  1.46)
During follow-up 481  2.42 ( 2.50 to  2.34)  2.38 ( 2.46 to  2.30)  2.36 ( 2.45 to  2.28)
Change in AHEI score
Increase ($1 SD) 717  0.99 ( 1.08 to  0.91)  0.99 ( 1.07 to  0.90)  1.65 ( 1.76 to  1.53)
Stable ( 1# SD <1) 3071  0.85 ( 0.92 to  0.79)  0.84 ( 0.90 to  0.78)  1.58 ( 1.68 to  1.47)
Decrease (< 1 SD) 681  0.76 ( 0.85 to  0.67)  0.75 ( 0.83 to  0.66)  1.46 ( 1.57 to  1.35)
Change in physical activity
Increase ($1 SD) 601  0.98 ( 1.07 to  0.88)  0.95 ( 1.05 to  0.86)  1.66 ( 1.78 to  1.54)
Stable ( 1# SD <1) 3312  0.86 ( 0.92 to  0.80)  0.85 ( 0.91 to  0.79)  1.56 ( 1.66 to  1.46)
Decrease (< 1 SD) 556  0.77 ( 0.87 to  0.68)  0.76 ( 0.85 to  0.66)  1.46 ( 1.58 to  1.34)
*Model 1: Adjusted for sex, age at baseline, ethnicity and duration of follow-up.
yModel 2: As model 1 and additionally adjusted for education level, BMI at baseline and long-standing illness at baseline.
zModel 3: As model 2 with predictors mutually adjusted.
AHEI, alternate healthy eating index; BMI, body mass index; LDL, low-density lipoprotein.
Table 3 Relative change in serum LDL-cholesterol (mmol/l) between the baseline (1991e3) and
follow-up (2003e4) screening as a function of the use of lipid-lowering drugs, healthy diet and physical
activity (N¼4469)
n
Mean relative change in LDL-cholesterol (mmol/l) and p value for difference
Model 1* Model 2y Model 3z
Start of lipid-lowering drugs
None 3954 0 Reference 0 Reference 0 Reference
Baseline 34  1.09 <0.001  1.09 <0.001  1.14 <0.001
During follow-up 481  1.81 <0.001  1.77 <0.001  1.77 <0.001
Change in AHEI score
Increase ($1 SD) 717  0.14 <0.001  0.14 <0.001  0.07 0.03
Stable ( 1# SD <1) 3071 0 Reference 0 Reference 0 Reference
Decrease (< 1 SD) 681 0.10 0.02 0.10 0.02 0.12 <0.001
Change in physical activity
Increase ($1 SD) 601  0.11 0.007  0.10 0.02  0.10 0.005
Stable ( 1# SD <1) 3312 0 Reference 0 Reference 0 Reference
Decrease (< 1 SD) 556 0.09 0.04 0.09 0.03 0.10 0.004
*Model 1: Adjusted for sex, age at baseline, ethnicity and duration of follow-up.
yModel 2: As model 1 and additionally adjusted for education level, BMI at baseline and long-standing illness at baseline.
zModel 3: As model 2 with predictors mutually adjusted.
AHEI, alternate healthy eating index; BMI, body mass index; LDL, low-density lipoprotein.
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We found an overall decrease in the LDL-cholesterol concentra-
tion in the Whitehall II cohort of civil servants over 11 years of
follow-up. The degree of decline was associated with an
increased use of lipid-lowering drugs, improvements in dietd
especially the ratio of white to red meat consumption and the
ratio of polyunsaturated to saturated fatty acids intakedand an
increase in physical activity. In this population, the contribution
of changes in diet and physical activity were modest compared
with pharmacological treatment among individuals at high risk
of CVD. However, a successful implementation of lipid-
lowering drug treatment for the relatively small group of high-
risk individuals and a favourable change in diet and physical
activity in the large group of people with a non-optimal lifestyle
were estimated to result in largely similar declines in LDL-
cholesterol in the total cohort. These ﬁndings support the use of
multifaceted intervention strategies for prevention.
In many previous studies, a decrease in the LDL-cholesterol
concentration has been assessed by comparing cross-sectional
surveys repeated over time: in the INTERGENE and
GOTeMONICA study (1985, 1990, 1995 and 2002),
9 in the
French MONICA study (1996 and 2007),
10 in the studies
conducted in Catalonia, Spain (1992 and 2003)
11 and in Gerona,
Spain (1995, 2000 and 2005).
12 This design captures time trends
but, unlike the prospective cohort design employed in the
present study, does not allow an estimation of within-subject
changes in LDL-cholesterol, or in their predictors.
Our study conﬁrms the ﬁndings of the few previous cohort
studies on changes in total or LDL-cholesterol among middle-
aged individuals. In an Australian population-based cohort
study, Buyken et al
35 reported a decrease of 0.7 mmol/l in LDL-
cholesterol between 1992 and 2004, comparable with the
0.9 mmol/l decrease in our study. Two other cohort studies, the
New Zealand Workforce Diabetes Survey
19 and the American
Physicians’ Health Study,
36 also reported a decline in LDL-
cholesterol from 1988 to 1997 and from 1982 to 1997, respec-
tively. In the Framingham Heart Study,
37 there was a slight
increase in LDL-cholesterol over time, but these analyses did not
include individuals on lipid-lowering or hormone replacement
therapies, or those with prevalent CVD. Randomised trials have
shown lipid-lowering drugs,
38 39 diet modiﬁcation
39e42 and
endurance exercise training
42e44 to be effective in lowering LDL-
cholesterol concentrations. The present results, obtained from
an observational study, add to the knowledge from randomised
controlled trials in which the effect size is dependent on speciﬁc
interventions.
There are a few caveats to the results reported here. First, total
cholesterol and triglycerides were not measured using the same
enzymatic methods at both study phases; but HDL-cholesterol
was assessed using the dextran sulphateemagnesium precipita-
tion method at baseline and the direct homogeneous method at
follow-up.
23 These protocol changes might have affected the
estimation of absolute LDL levels. However, this is an unlikely
source of major bias because both methods have been validated
and certiﬁed by the Cholesterol Reference Method Laboratory
Network at the Centers for Disease Control and Prevention,
45 46
and agreement between the methods is high, with a correlation
coefﬁcient of 0.98, slope 0.98 and mean bias 0.05 mmol/l.
47 If
the level of HDL-cholesterol was ‘overestimated’ by 0.05 mmol/l
at follow-up in the present study, the method-related decrease in
LDL-cholesterol between baseline and follow-up would have
been approximately 0.06 mmol/l, which is small compared with
the mean observed decrease of 0.86 mmol/l. Furthermore, bias
resulting from the change in the method of assessing HDL-
cholesterol is likely to be independent of the measurement of the
predictors and thus should not unduly bias our ﬁndings on
relative differences in changes in LDL-cholesterol between
subgroups.
Second, physical activity and, to a greater extent, dietary
intake, are difﬁcult to measure accurately; whereas it is likely
that the use of lipid-lowering drugs is recalled with greater
precision. We may therefore have underestimated the effects of
diet and physical activity on LDL-cholesterol decline. Further-
more, it is possible that we underestimated the contribution of
diet because our analysis did not fully capture effects arising
from externally driven secular changes in dietary patterns. For
example, recommendations from the National Institute for
Health and Clinical Excellence encourage manufacturers,
caterers and producers to reduce the amount of saturated and
trans fatty acids in all food products and replace them, if needed,
by polyunsaturated and monounsaturated fatty acids.
48 Such
guidance, if successful in reducing ‘bad’ cholesterol in marketed
foods, could, potentially, have a notable impact on the number
of cardiovascular events at the population level, as is clear from
the results from the recent meta-analysis of randomised
controlled trials.
49
Third, regression towards the mean is a potential source of
bias in observational studies with repeat outcome measures.
32
Regression to the mean arises from random errors in measure-
ment and should be relatively independent of the use of lipid-
lowering drugs or lifestyle. In the present study, these factors
remained important predictors of reduced LDL levels in
Table 4 Estimated beneﬁcial effect of lipid-lowering drugs, healthy diet and physical activity on LDL change in the population at risk and the total
cohort
Intervention
Mean LDL-cholesterol (mmol/l) change
Population at risk at baseline Total cohort (n[4469)
Total N (N already
following the intervention)* Observed
After
interventiony Observed
After
interventiony
Start lipid-lowering drugs 858z (515)  1.04  3.81  0.86  1.07
$1 SD increase in the AHEI diet score* 3457x (684)  0.84  0.92  0.86  0.91
$1 SD increase in the no of hours of
physical activity*
2190{ (383)  0.85  0.96  0.86  0.90
*Here intervention stands for use of a lipid-lowering drug among those needing such a treatment according to the European guidelines, improving diet among those with an AHEI score less than
60, or increasing the duration of physical activity among those with less than 2.5 h/week. 1 SD increase in the AHEI score is 0.6 point and 1 SD increase in physical activity is 17 min/week
yDecline in LDL-cholesterol estimated for participants who met the criteria for intervention based on effects shown in table 3, model 3.
zParticipants with cardiovascular disease risk score of 5% or greater or prevalent coronary heart disease or diabetes at baseline, or lipid-lowering medication at baseline or follow-up.
xParticipants with an AHEI score of less than 60 at baseline.
{Participants with physical activity for less than 2.5 h/week at baseline.
AHEI, alternate healthy eating index; LDL, low-density lipoprotein.
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terol at baseline, a group whose measures are likely to contain
more measurement error, suggesting that regression to the mean
had, if anything, little impact on our ﬁndings.
Fourth, by deﬁnition, occupational cohorts such as Whitehall
II are ﬁtter than the general population due to the healthy
worker effect. The feedback provided to participants after
medical screening phases of the study about their coronary risk
factors may also have promoted healthier lifestyles, as discussed
in relation to the Framingham study.
37 Further research is
therefore needed to examine the generalisability of our ﬁndings.
With the limitations of our study in mind, we conclude that
declining trends in LDL-cholesterol seem to be independently
associated with the use of lipid-lowering therapy and favourable
lifestyle changes. Our ﬁndings suggest that more should be done
to reduce the under-treatment of dyslipidaemia and promote
lifestyle modiﬁcations in order to accelerate further the favour-
able population trends in LDL-cholesterol.
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